Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized controlled trial by van Dijk, S. et al.




Susan J. van Dijk, Jing Zhou, Timothy J. Peters, Michael Buckley, Brodie Sutcliffe, Yalchin Oytam, 
Robert A. Gibson, Andrew McPhee, Lisa N. Yelland, Maria Makrides, Peter L. Molloy and Beverly S. 
Muhlhausler 
Effect of prenatal DHA supplementation on the infant epigenome: results from a randomized 
controlled trial 
Clinical Epigenetics, 2016; 8(1):114-1-114-13 
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), 
which permits unrestricted use, distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons 
license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver 
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this 
article, unless otherwise stated. 






























Effect of prenatal DHA supplementation on
the infant epigenome: results from a
randomized controlled trial
Susan J. van Dijk1*, Jing Zhou2, Timothy J. Peters3, Michael Buckley3, Brodie Sutcliffe1, Yalchin Oytam4,
Robert A. Gibson2,5, Andrew McPhee6, Lisa N. Yelland5,7, Maria Makrides5, Peter L. Molloy1
and Beverly S. Muhlhausler2,5
Abstract
Background: Evidence is accumulating that nutritional exposures in utero can influence health outcomes in later
life. Animal studies and human epidemiological studies have implicated epigenetic modifications as playing a key
role in this process, but there are limited data from large well-controlled human intervention trials.
This study utilized a large double-blind randomized placebo-controlled trial to test whether a defined nutritional
exposure in utero, in this case docosahexaenoic acid (DHA), could alter the infant epigenome. Pregnant mothers
consumed DHA-rich fish oil (800 mg DHA/day) or placebo supplements from 20 weeks’ gestation to delivery.
Blood spots were collected from the children at birth (n = 991) and blood leukocytes at 5 years (n = 667). Global
DNA methylation was measured in all samples, and Illumina HumanMethylation450K BeadChip arrays were used
for genome-wide methylation profiling in a subset of 369 children at birth and 65 children at 5 years.
Results: There were no differences in global DNA methylation levels between the DHA and control group either
at birth or at 5 years, but we identified 21 differentially methylated regions (DMRs) at birth, showing small DNA
methylation differences (<5%) between the treatment groups, some of which seemed to persist until 5 years.
The number of DMRs at birth was greater in males (127 DMRs) and in females (72 DMRs) separately, indicating a
gender-specific effect.
Conclusion: Maternal DHA supplementation during the second half of pregnancy had small effects on DNA
methylation of infants. While the potential functional significance of these changes remains to be determined,
these findings further support the role of epigenetic modifications in developmental programming in humans
and point the way for future studies.
Trial registration: Australian New Zealand Clinical Trials Registry (ANZCTR), ACTRN12605000569606 and
ACTRN12611001127998
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Background
Human and animal studies have provided clear evidence
that the environment during critical periods of develop-
ment can increase the risk of a wide range of diseases in
postnatal life [1, 2]. This programming of disease risk may
be mediated, at least in part, by (semi) permanent epigen-
etic alterations which can regulate gene expression and
thereby affect phenotype. In animal studies, controlled
nutritional interventions before or during pregnancy have
been shown to significantly affect the epigenome and to
be associated health outcomes [3, 4]. In humans, epi-
demiological studies have provided evidence that different
intrauterine exposures, including malnutrition [5, 6],
smoking [7], toxicants [8] and micronutrient deficiencies
[9], can affect the epigenome of the infant. A limited
number of small clinical trials involving specific prenatal
interventions (i.e. micronutrient supplementation [10, 11]
and weight loss surgery [12]) have produced similar find-
ings; however, large, well-controlled trials in humans are
required to confirm the ability of defined nutrition in
pregnancy to impact on the infant epigenome.
Fish oil supplements which contain the long chain n-3
polyunsaturated fatty acids (n-3 LCPUFAs) eicosapenta-
enoic acid (EPA) and docosahexaenoic acid (DHA) are
commonly consumed during pregnancy. These fatty
acids have received attention for their health benefits,
specifically in relation to diseases with an inflammatory
component [13, 14]. DHA also plays an important role
in the development of the brain and central nervous
system [15], and exposure to an increased DHA supply
in utero has been associated, in some studies, with a
reduced risk of allergy and improved metabolic health
outcomes in postnatal life [16, 17]. The mechanisms
underlying these effects are unclear; however, there have
been suggestions that they may be epigenetically mediated.
In rats, intake of n-3 LCPUFAs during pregnancy was
shown to change DNA methylation levels in the fatty
acid desaturase promoter in the liver of the offspring
[18]. In other studies, an effect of DHA on methylation
in the placenta via the alteration of one carbon metabol-
ism has been proposed [19, 20]. In adult humans, differ-
ences in DNA methylation have been identified between
people with high and low n-3 PUFA intakes [21, 22], and
n-3 PUFA supplementation has been shown to induce
changes in methylation at specific CpG sites [23].
There are currently only two studies which have inves-
tigated the effects of increased prenatal DHA exposure
on DNA methylation in the neonate. One trial in 260
subjects used a candidate gene approach and showed
that maternal DHA supplementation induced small
changes in global DNA methylation and methylation at
IGF2/H19 imprinted genes in cord blood [24, 25], while
another trial in 70 subjects assessed genome-wide DNA
methylation in CD4+ T cells from cord blood and did
not find any substantial effect of prenatal DHA supple-
mentation [26]. Thus, additional genome-wide methyla-
tion studies with large sample sizes are needed to
determine the impact of prenatal DHA supplementation
on the epigenome of the infant, and whether this could
underlie the effects of maternal DHA supplementation
on infant and child outcomes.
The aim of this study was to utilize DNA samples
obtained from a large randomized controlled trial,
DOMInO (DHA to Optimise Mother Infant Outcome),
to determine the impact of a defined nutritional inter-
vention, specifically a high-dose DHA supplement,
during the second half of pregnancy on the epigenome
of the children at birth and at 5 years of age.
Results
Subject characteristics
Characteristics of the mothers and children included in
the study are summarized in Table 1. There were no
significant differences in the key characteristics between
the DHA and the control group pre-randomization, either
in the whole study population or in any of the subsets
used for genome-wide methylation analysis. As expected,
there were significant differences in cord blood DHA
concentrations between the groups post randomization.
Global DNA methylation
No significant differences in LINE1 hypomethylation
levels were found between the control and DHA-
supplemented groups either at birth or at 5 years of age
(Table 2). Furthermore, no association was found between
DHA concentration in cord blood and LINE1 DNA
methylation in the whole study group, or when separated
by treatment group or gender (data not shown). Consist-
ently lower LINE1 hypomethylation levels were found in
males compared to females at both time points (P < 0.001)
and both in males and females mean LINE1 hypomethyla-
tion levels were lower at 5 years compared to birth
(P < 0.001), independent of treatment group.
At birth no significant differences between the treat-
ment groups were found in mean DNA methylation
levels by annotation across all probes on the 450K array
(Additional file 1: Table S1). Small DNA methylation dif-
ferences between males and females were found across
all designations, with males showing higher DNA methy-
lation levels than females. These results were similar at
age 5 years (data not shown) and consistent with the
lower hypomethylation levels of LINE1 repeats observed
in males compared to females.
Genome-wide DNA methylation
Variable methylated sites and regions
CpG sites that display high inter-individual variation in
DNA methylation levels are considered to be most
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susceptible to environmental effects, including nutrition
[27]. In our study population, we first identified the most
variable sites and variable methylated regions (VMRs) in
the whole population, irrespective of treatment group. In
total, 0.4% of the probes on the arrays showed a variance
in methylation beta values of >0.01 across the study
population at birth and 0.6% of the probes showed a
variance of >0.01 across the study population at age
5 years.
In the study population at birth, 5296 VMRs were
identified, and 4214 VMRs were identified at 5 years of
age. Of these VMRs, 3135 showed either complete or
partial overlap across the two time points (Additional
file 1: Table S2).
Multiple highly significant VMRs were located in
probe dense, polymorphic genomic regions such as the
Major Histocompatibility Complex (MHC) region on
chromosome 6 (HLA-DQB1 and HLA-DRB1) and in the
olfactory receptor gene OR2L13. Visualization of individ-
ual methylation beta values (Fig. 1) for VMRs revealed
that while many CpGs within a VMR showed an even
distribution of beta values across samples, for some
CpGs within VMRs, such as for HOOK2 and NINJ2
(Fig. 1), the samples clustered into two or three distinct
groups, indicating that these VMRs were likely due to
genetic variation. Thus, children that were homozygous
for a particular variant displayed either low or high
methylation levels while heterozygous children displayed
an intermediate level of methylation, often for multiple
consecutive CpG sites. Such genetic influence on levels
of DNA methylation may extend in cis across hundreds
of kilobases [28, 29], and genetic and environmental
variation may further interact to determine DNA methy-
lation levels [30].
Effect of prenatal DHA supplementation on genome-wide
DNA methylation
We first analysed the DNA methylation data at an
individual probe level and found no differentially meth-
ylated probes between the DHA and control groups at
birth at an FDR-adjusted P value of <0.05. When ana-
lyses were undertaken separately in males and females,
no differentially methylated probes were found in males,
but in females, one probe (cg00870514, near the tran-
scription start site of RAB11FIP4) showed significantly
higher DNA methylation levels in the DHA compared to
Table 1 Characteristics of mothers and children in the control and DHA-supplemented groups










Flinders Medical Centre and private hospitals, no. (%) 59 (31.1) 64 (35.8) 199 (38.5) 188 (39.7)
Women’s and Children’s Hospital, no. (%) 131 (68.9) 115 (64.2) 318 (61.5) 286 (60.3)
Primiparous, no. (%) 68 (35.8) 60 (33.5) 212 (41.0) 192 (40.5)
Mother’s age at trial entry, mean (SD), years 30.2 (5.9) 30.2 (5.5) 29.8 (5.6) 29.7 (5.5)
Mother smoking at trial entry, no. (%) 19 (10.0) 15 (8.4) 60 (11.6) 52 (11.0)
Duration of gestation, median (IQR), weeks 39.9 (38.6–40.7) 39.7 (39–40.5) 39.7 (38.7–40.7) 39.6 (38.9–40.4)
Birth weight, median (IQR), g 3542 (3160–3859) 3510 (3260–3832) 3500 (3160–3820) 3510 (3190–3798)
Child male sex, no. (%) 92 (48.4) 93 (52.0) 260 (50.3) 242 (51.1)
DHA in cord blood, mean (SD), % of total fatty acids 7.9 (1.8)* 6.4 (1.5) 7.8 (1.8)* 6.3 (1.5)
Abbreviations: DHA docosahexaoneic acid, IQR interquartile range
*Difference between the DHA and control group P < 0.001
Table 2 LINE1 hypomethylation at birth and at 5 years for the DHA and control group
Subgroup DHA group mean (SD) Control group mean (SD) Treatment effect DHA-control adjusteda (95% CI) P value, adjusteda
Birth 1.47 (0.57)b 1.43 (0.45) 0.04 (−0.02, 0.10) 0.211
5 years 0.99 (0.15) 0.99 (0.16) 0.00 (−0.02, 0.03) 0.706
Birth, female 1.56 (0.64) 1.50 (0.48) 0.06 (−0.04, 0.15) 0.229
Birth, male 1.39 (0.49) 1.36 (0.42) 0.03 (−0.06, 0.11) 0.583
5 years, female 1.04 (0.16) 1.03 (0.17) 0.01 (−0.03, 0.04) 0.655
5 years, male 0.95 (0.13) 0.95 (0.15) 0.00 (−0.03, 0.03) 0.837
All children who had any global DNA methylation data were used for this analysis; 522 children had data at birth and 5 years, 469 had data at birth only, 141 had
data at 5 years only
aAdjustment was made for centre, parity and gender
bLINE1 methylation values are expressed as relative hypomethylation values compared to a reference sample
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the control group (0.54 ± 0.03 vs 0.51 ± 0.03, adjusted
P value =0.004). A comparison of the limma P value
and t-statistic distributions for the treatment group
analyses in males, females and the whole population
showed that, overall, the P values in males were
slightly lower than in females or the combined popu-
lation (Additional file 2: Figure S1).
Methylation at neighbouring CpG sites is often corre-
lated, so extra analyses were done to identify differen-
tially methylated regions (DMRs); genomic regions of
multiple consecutive probes showed differential methy-
lation between the treatment groups. This regional
grouping of probes provides greater power to identify
methylation differences that may be associated with
functional elements. The DMR analysis in the combined
population identified 21 DMRs between the treatment
groups at birth (Table 3). Adjustment for cell mixture
did not significantly change the main study outcomes;
DMRs identified in unadjusted data are presented in
Table 3 and adjusted data in Additional file 1: Table S3).
Of the 21 identified DMRs, 18 DMRs were associated
with a gene and 3 DMRs were intergenic. We then
determined the overlap of DMRs with VMRs and found
that about half of the DMRs were either completely
overlapping or contained within a VMR, which supports
the prevailing hypothesis that highly variable regions are
most susceptible to alteration by the (prenatal) environ-
ment [27, 31].
Overall, methylation differences between the DHA and
control groups were modest, with maximum group beta
differences of 4.5% for single probes within DMRs. The
differences between the DHA and control groups were,
however, consistent over multiple consecutive probes
within each DMR (Fig. 2). The majority of the DMRs
(17/21) showed lower methylation levels in the DHA
group compared to the control group.
The DMRs identified at birth were located in genes
with a variety of functions, including lipid exchange
between membranes (ESYT3 [32]), plasma membrane
function (SLC12A6 [33]), appetite regulation (CCK [34]),
immune function (RAET1L and LTB [35, 36]) and neu-
rodevelopment/brain function (SLC12A6, TRAK1,
LPHN3 and RFPL2 [33, 37, 38]).
We further analysed males and females separately.
When separated by gender, a greater number of DMRs
were identified both in males (127 DMRs) and females
(72 DMRs) (Additional file 1: Tables S4 and S5). Three
of these DMRs were identified in both males and
females (in ESYT3, TNXB and a region in chr 7) of
which one DMR (in ESYT3) showed methylation differ-
ences between treatment groups in the same direction in
males and females.
For the identification of the DMRs, we had relaxed
the default parameterization of DMRcate, which may
have increased the number of false positive DMRs.
We applied permutation testing to determine the like-
lihood that identified DMRs arose by chance. For the
combined as well as gender-specific analyses data, the
number of DMRs—combined data set (n = 21), males
(n = 127), females (n = 72)—were higher than the
median number of DMRs that would be expected by
chance alone (n = 10 for the combined set, n = 12 for
males, n = 13 for females and, Additional file 2: Figure
S2). This suggests that most of the identified DNA
methylation differences are true positive findings. Par-
ticularly for the gender-specific DMRs, the likelihood
of the numbers of DMRs observed occurring by


























































Fig. 1 Variable methylated regions (VMRs) at birth. Every dot represents the DNA methylation level for a child at a single probe within the VMR
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At 5 years of age, 10 DMRs, but no significant probes,
were identified between the DHA and the control
groups (Additional file 1: Table S6). All these DMRs
showed lower methylation levels in the DHA group
compared to the control group, consistent with the find-
ings at birth. The DMRs found at 5 years were all differ-
ent from the DMRs at birth. However, a comparison of
DNA methylation differences between treatment groups
at birth and at 5 years revealed that the methylation
changes for probes within the 21 DMRs identified at
birth, although not reaching genome-wide statistical sig-
nificance at age 5 years, were generally in the same dir-
ection at age 5 years (Fig. 3). In the case of the top most
significant DMRs at birth (in ESYT3 and at chr12), the
magnitude of the group differences in DNA methylation
at the two time points were very similar (Figs. 2 and 3).
For other DMRs, such as another DMR on chr 12
(DMR12 in Table 3 and in Fig. 3), DNA methylation dif-
ferences were present at birth, but no longer present at
age 5 years.
When comparisons between treatment groups at age
5 years were conducted separately in males and females,
45 DMRs were found in males and 10 DMRs were found
in females (Additional file 1: Tables S7 and S8). Six
DMRs in males were identified both at birth and at
5 years (Additional file 1: Tables S4 and S7), with lower
DNA methylation levels in the DHA compared to the
control group at both time points. Comparison of the
DNA methylation differences between groups in males
and females at both time points showed that, similar to
what was observed in the combined population, there
was a trend for maintenance of the differences between
treatment groups over time (Fig. 3).
Association of DNA methylation with DHA concentration
at birth
Previous analyses have shown that while the children in
the DHA group on average had higher DHA concentra-
tions in cord blood than the control group, there was
substantial overlap in DHA levels between the groups.
Therefore, in addition to comparing DNA methylation
between the treatment groups, we also investigated the
association between DNA methylation and the DHA
concentrations measured in cord blood. Methylation
Table 3 Differentially methylated regions between the DHA-supplemented and control group at birth
hg19 coordinates No. of
probes




1 chr3:138152837-138153763 12 926 ESYT3 TSS1500,TSS200,1stExon,5′UTR 5.75E−15 −0.045 Y
2 chr12:132293329-132293702 5 373 Intergenic 1.12E−07 −0.026 Y
3 chr15:34610829-34611069 4 240 SLC12A6 Body,1stExon,5′UTR,TSS200 4.99E−06 −0.011 Y
4 chr3:42306150-42307193 10 1043 CCK 5′UTR,1stExon,TSS200,TSS1500 6.05E−06 −0.012 Y
5 chr7:1882776-1883876 9 1100 MAD1L1 Body 8.75E−06 0.023 Y
6 chr2:48844728−48845068 8 340 GTF2A1L, STON1 TSS1500,Body,TSS200,1stExon,5′UTR 8.75E−06 −0.019 Y
7 chr6:166876490-166877038 7 548 RPS6KA2 Body 8.75E−06 0.022 Y
8 chr8:59058254-59058585 3 331 FAM110B 5′UTR 9.79E−06 −0.009 N
9 chr10:134221633-134222453 6 820 PWWP2B 3′UTR,Body 1.10E−05 −0.033 Y
10 chr3:42201314-42201898 6 584 TRAK1 TSS1500,Body,TSS200,1stExon 2.11E−05 −0.015 N
11 chr6:150346721-150347053 10 332 RAET1L TSS200,TSS1500 5.41E−05 −0.009 Y
12 chr12:7781004-7781431 5 427 Intergenic 2.15E−04 −0.044 Y
13 chr6:1619162-1619687 3 525 Intergenic 2.62E−04 −0.012 N
14 chr8:117950244-117950504 7 260 C8orf85 TSS1500,TSS200,1stExon,5′UTR 4.08E−04 −0.01 N
15 chr4:62382932-62383240 4 308 LPHN3 Body 6.20E−04 −0.019 N
16 chr4:1107202-1107259 2 57 RNF212 1stExon,5′UTR 6.45E−04 −0.01 N
17 chr17:75446431-75446661 6 230 SEPT9 TSS200,Body,1stExon,5′UTR 7.94E−04 −0.013 N
18 chr6:31549929-31550090 2 161 LTB Body,1stExon 8.92E−04 −0.008 N
19 chr22:32599511-32599516 2 5 RFPL2 TSS200,5′UTR,TSS1500 9.17E−04 −0.037 Y
20 chr20:13620031-13620048 2 17 TASP1 TSS1500 9.61E−04 0.012 N
21 chr1:156261200-156261207 2 7 TMEM79 Body 9.77E−04 0.01 N
Abbreviations: DMR differentially methylated region, VMR variable methylated region, TSS1500 1500 base pairs from the transcription start site, TSS200 200 base
pairs from the transcription start site, 5′UTR 5′ untranslated region, 3′UTR 3′ untranslated region
aSmallest P value for a probe in the DMR
bLargest DNA methylation (beta value) difference between the DHA and control group for a probe within the DMR
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levels for 349 probes (FDR P value <0.05) were signifi-
cantly associated with DHA concentration. Because of
the known association of DHA concentration with gesta-
tional age, gestational age was added as a covariate to
the model, and no probes remained significantly differ-
ent between groups after this adjustment. In addition,
no probes were found to be significantly associated with
cord blood DHA concentration when the analyses were
performed separately by group or sex.
Discussion
In this large, well-characterized study population, we
showed that maternal DHA supplementation across the
second half of pregnancy was associated with modest
alterations in DNA methylation in a small subset of gen-
omic regions within genes involved in diverse biological



















































































































Fig. 2 Differentially methylated regions (DMRs) between the DHA
and control group. DMRs identified at birth (a, c, e, g, h) and the
corresponding region at age 5 years (b, d, f). The DHA group is shown
in blue, and the control group in red. The bottom and top of the box
represent the 25th and 75th percentile of DNA methylation within the























































































Fig. 3 DNA methylation differences between treatment groups for
probes within significant differentially methylated regions (DMRs).
The differences in beta values between the DHA and the control
group at birth and age 5 years are shown for probes that are part of
significant DMRs between the DHA and control group at birth. DNA
methylation differences are shown for all children (a) and males
(b) and females (c) separately. The probes are coloured by DMR;
DMR1 (ESYT3) in black in the lower left corner, DMR2 (chr12) in blue
in the lower left corner, DMR12 (chr12) in blue in the upper left corner
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processes. The strengths of our study include the ran-
domized design, the large sample size and the DNA
methylation analysis at two time points, which enabled
us to determine whether any DNA methylation changes
induced by DHA persisted over time.
To the best of our knowledge, there are currently only
two other, smaller, randomized controlled trials that have
investigated the effects of prenatal DHA supplementation
on the epigenome at birth [24–26], and our study is the
first to determine whether any epigenetic influences of
DHA persist in childhood. In line with our findings, these
previous studies reported minor or no effects of prenatal
DHA supplementation on DNA methylation in either
cord blood [24, 25] or infant CD4+ T cells [26]. In the
study by Lee et al., a small effect of DHA supplementation
on global DNA methylation was reported in children from
mothers who smoked during pregnancy, while an effect
on IGF2 promoter methylation was identified only in pre-
term infants [24, 25]. This suggests that prenatal DHA
exposure may have a greater impact on the epigenome in
some subgroups. We did not find specific effects of DHA
on the epigenome in subpopulations of preterm infants or
in children from smokers (data not shown), but our study
may have been underpowered to detect differences in
these small subgroups.
The study by Amarasekera et al. included 70 mother-
child pairs, and although a high dose of DHA was con-
sumed during pregnancy (~2 g/day), no significant effect
on DNA methylation was observed [26]. In agreement
with our results, there were no probes associated with
cord blood DHA concentrations in Amarasekera’s study.
However, it is difficult to separate effects of cord blood
DHA concentration on DNA methylation from those of
gestational age. Both DNA methylation profiles and cord
blood DHA have been reported to be related to gesta-
tional length [39]. Importantly, in the DOMInO trial,
DHA supplementation resulted in a significant in-
crease in the length of gestation and cord blood DHA
concentrations were positively correlated with gesta-
tional age [40]. Further studies are needed to assess
the independent contribution of these variables to
DNA methylation profiles.
The effects of DHA supplementation on DNA methy-
lation in our study showed a clear gender effect and
appeared to be more pronounced in males compared to
females, suggesting that the epigenome of males may be
more susceptible to prenatal exposure to DHA. This is
in line with the results of a number of previous studies,
which have reported sex differences in response to the
prenatal environment, with most identifying more pro-
nounced effects in males [41–43]. Differences in placen-
tal adaptations to changes in the prenatal environment
have been suggested as a mechanism underlying these
sex-specific effects [41, 43]. Widespread sex differences
in DNA methylation, independent of DHA, may also
have influenced the response.
We saw limited overlap between the significant DMRs
at birth and at age 5 years in our study population. How-
ever, DNA methylation differences between treatment
groups for a number of the DMRs identified at birth,
while not statistically significant, were still present at age
5 years. Given the small size of the DNA methylation
differences between treatment groups relative to their
within-group variance, it is possible that there was insuf-
ficient statistical power in the smaller subset of children
assessed at age 5 years for these differences to reach
genome-wide statistical significance. Our results do,
however, raise the possibility that small DNA methyla-
tion changes induced by increased DHA exposure may
persist over time, at least to some extent. Genetic
variation between treatment and control groups, alone
or interacting with DHA supplementation [30, 44], could
contribute to the observation of persistence over time
for some DMRs. However, the similarity of effect in the
birth comparison and the subset of subjects assessed at
5 years suggests the effects are predominantly due to
treatment. Larger studies assessing multiple time points
in childhood are needed to confirm this.
For many DMRs, the initial methylation differences
between groups were no longer present at 5 years of age.
This is not unexpected, since the maternal environment
may still have a proportionally high impact on DNA
methylation in the immediate postnatal period in com-
parison to later childhood, at which time the number of
postnatal exposures with the potential to modify the
epigenome accumulate and the effect of prenatal expo-
sures is diluted. In support of this, studies investigating
the impact of maternal smoking on the child’s epigenome
have demonstrated that only part of the smoking-induced
epigenetic changes persisted into adolescence [45].
Overall, the data from both our study and the two previ-
ous DHA intervention trials do not support the existence
of a strong effect of DHA supplementation during the sec-
ond half of pregnancy on DNA methylation in blood cells
of infants. This could be due to a variety of reasons. First,
the DNA methylation profile in blood may not necessarily
reflect the profile of target tissues, particularly those which
contain relatively high proportions of DHA such as the
brain or adipose tissue. An alternate possibility is that
DHA may have had effects on the epigenome via mecha-
nisms other than DNA methylation, such as histone modi-
fications, that were not investigated in our study. The
natural inter-individual variation in blood cell populations
may also have introduced variation in DNA methylation,
thereby masking effects of the intervention. However, this
possibility seems unlikely since the outcomes of our study
were very similar when the analyses were adjusted for cell
mixture [46]. A study using purified CD4+ T cells also
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found no substantial effects of prenatal DHA supplemen-
tation on DNA methylation in the newborn [26].
The modest effects of maternal DHA supplementation
are consistent to some extent with the findings of the
DOMInO trial and its associated follow-up studies,
which have reported modest or no effect of the maternal
DHA supplementation on growth, neurodevelopment
and fat mass [40, 47, 48]. Positive effects of DHA were
noted for immune-related outcomes at age 1 year in a
subset of the DOMInO children at high hereditary risk
of allergic disease [49]. This suggests that specific sub-
groups of children benefit more from the intervention
and may also show more pronounced changes in DNA
methylation. The timing of the DHA supplementation
may have limited the impact on the epigenome, since
the major period of epigenetic remodelling of the fetus
is early in pregnancy, and the intervention did not begin
until ~20 weeks gestation in the DOMInO trial. While
there are major practical and ethical complications
involved in testing the effects of interventions applied
earlier in pregnancy, studies on naturally occurring
changes of food availability due to seasonal differences
in rural Gambia or supply restriction in the Dutch
Hunger Winter have provided evidence that exposures
early in pregnancy generally have a more profound ef-
fect on the epigenome compared to exposures later in
gestation [5, 6].
Overall, while the observed changes in DNA methy-
lation in our study were relatively small, small
changes in DNA methylation in regulatory parts of
the genome, such as in gene promoter or enhancers,
can nevertheless associate with significant effects on
gene regulation. Whether the DNA methylation differ-
ences observed in our study translate into functional
consequences for gene expression and phenotype remains
to be determined.
Conclusions
We demonstrated, using a large, randomized controlled
trial, that maternal DHA supplementation across the
second half of pregnancy had modest effects on DNA
methylation at specific regions of the genome in blood
cells of children at birth, some of which seem to persist
until 5 years of age. We also observed sex-specific effects
of the intervention on DNA methylation, and in general,
effects appeared to be more pronounced in males than
females. There is still relatively little human data on the
magnitude and extent of epigenetic changes impacted by
nutrition during pregnancy. Our results adds to the
growing body of evidence implicating epigenetic regula-
tion as a mechanism underlying the impact of nutri-
tional exposures in utero on infant and child health in




The present study is part of the EpiSCOPE Consortium
[50] and uses biological samples collected within the first
few days after birth (neonatal samples) and at 5 years of
age, as part of the growth and insulin resistance follow-
up of children whose mothers participated in a regis-
tered, multi-centre, double-blind randomized controlled
trial, the DOMInO trial (ACTRN12605000569606 and
ACTRN12611001127998). Details of the design of the
DOMInO trial and the follow-up study have been previ-
ously published [40, 48]. Briefly, women less than
21 weeks’ gestation were randomly allocated to consume
three capsules a day providing either ~800 mg/day DHA
and ~100 mg/day EPA (Incromega 500 TG, Croda
Chemicals, East Yorkshire, UK) or a similar dose of
vegetable oil without DHA, until delivery. The
randomization was performed using a computer-driven
telephone randomization service with stratification by
enrolling centre and parity (first or subsequent birth).
Adherence to the intervention was monitored, and DHA
concentrations were measured in plasma phospholipids
from cord blood according to previously reported
methods [40].
DOMInO participants who had been enrolled at one
of the Adelaide centres (Women’s and Children’s
Hospital or Flinders Medical Centre; n = 1660) and had
not withdrawn or died were contacted when their child
was 2.5 years of age and invited to participate in the
growth and insulin resistance follow-up of the DOMInO
children at 3 and 5 years of age. Those who provided
written informed consent (n = 1531) were enrolled in the
follow-up study, and their child was invited to attend
clinic appointments at 3 and 5 years of age. At the
5-year appointments, between 25 March 2009 and 4
October 2013, a blood sample was collected from those
children whose primary carer consented to this proced-
ure. The blood samples were collected into EDTA blood
tubes and placed on ice; most samples were processed
within 4 h and all samples within 24 h of collection.
DNA was isolated from the buffy coat of the samples
(n = 667). For the neonatal samples, written informed
consent was sought from all participants involved in
the growth and insulin resistance follow-up study to
access their child’s newborn screening card for the
purposes of isolating DNA for (epi)genetic studies. All
procedures were conducted in accordance with the
trial protocol and approved by the local institutional
ethics committees.
Sample collection and DNA extraction
Neonatal screening (Guthrie) cards were retrieved from
a dedicated storage facility, in which the cards had been
stored at room temperature for between 5 and 7 years
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prior to use. Blood spot punches were taken from Guth-
rie cards of 991 DOMInO children whose mothers had
given consent. DNA was extracted using GenSolve tech-
nology (IntegenX, Pleasanton, CA, USA) followed by
purification using the QIAamp DNA micro kit (Qiagen,
Doncaster, VIC, Australia) and an additional ethanol
precipitation step. Briefly, three punches from a Guthrie
card, each 3 mm in diameter, were incubated for 1 h at
65 °C in 620 μL recovery solution A in 1% lithium dode-
cyl sulfate, in the presence of protease. After incubation,
the blood spots were transferred to a spin basket in a
new tube and centrifuged for 2 min at full speed for op-
timal recovery of the lysate. Subsequently, the spin bas-
ket and blood spots were discarded and 20 μL of
recovery solution B was mixed with the lysate before
proceeding with the DNA purification. A volume of
600 μL ethanol was added to the lysate and loaded onto
a QIAamp micro column. The DNA was purified on the
column according to the manufacturer’s instructions
with the modification that the columns and the elution
buffer were incubated for 10 min at 70 °C prior to the
final centrifugation step. After elution, the DNA was
ethanol precipitated with 30 μg Glycoblue as a carrier
(Life Technologies, Mulgrave, VIC, Australia) and the
resulting pellet was dissolved in 60 μL AE buffer with
0.01% Triton X100.
DNA from the peripheral blood leukocyte samples col-
lected at age 5 years was extracted using the QIAquick
DNA extraction kit (Qiagen, Doncaster, VIC Australia) as
per the manufacturer’s instructions. The quality and quan-
tity of all DNA samples was assessed using a Nanodrop
spectrophotometer and the Quant-iT Picogreen dsDNA
assay (Life Technologies, Mulgrave, VIC, Australia).
DNA methylation
Global DNA methylation
Hypomethylation levels in long interspersed nuclear
elements-1 (LINE-1) in all newborn (n = 991) and 5-year
(n = 663) DNA samples were quantified using the end-
specific PCR assay [51]. In this assay, the relative cutting
of the DNA by the methylation-sensitive enzyme HpaII
(GeneSearch, Arundel, QLD, Australia) is compared with
that of the methylation-insensitive enzyme Dra1 (Gene-
Search, Arundel, QLD, Australia) to give a measure of
DNA hypomethylation. The method depends upon the
use of 5′-tailed, 3′-blocked oligonucleotides called facili-
tator oligonucleotides (Foligos). Only cut DNAs with
specific matching sequences at their 3′ ends can copy
the tails of the Foligos and thus become tagged and
available for subsequent PCR. Samples were run in trip-
licate and the LINE1 hypomethylation levels in the DNA
samples were normalized relative to an external refer-
ence DNA sample from human blood (Roche Applied
Sciences, Dee Why, NSW, Australia).
The effect of DHA supplementation on global methy-
lation was analysed using a linear regression model with
a generalised estimating equation (GEE) to account for
repeated measures. A treatment-by-time interaction
term was included in the model and estimates of treat-
ment effect were derived separately for birth and 5 years.
Both unadjusted and adjusted analyses were performed,
with adjusted analyses including centre, parity and sex
as covariates. The possibility of effect modification by in-
fant sex was investigated by fitting separate models for
birth and 5 years, with a treatment-by-sex interaction
term included in the model; separate estimates of treat-
ment effect were derived for males and females. Differ-
ences in global DNA methylation according to sex and
time, irrespective of the treatment group, were investi-
gated by fitting a separate sex-by-time model with GEE
to account for repeated measures.
Genome-wide DNA methylation analysis
Genome-wide, site-specific DNA methylation was
assessed using the Illumina Infinium HumanMethyla-
tion450 BeadChip (450K) in samples from a subset of
369 children at birth and a subset of 65 children at age
5 years (Fig. 4). The subset at birth comprised those chil-
dren for which a sufficient quantity of DNA was ob-
tained from the neonatal screening card (>250 ng) and
for whom DNA samples were also available at age
5 years. The subset at age 5 was randomly selected from
the full data set by an independent statistician to contain
an equivalent number of males and females and an
equivalent number from each treatment group.
All selected DNA samples were submitted to the
Australian Genome Research Facility (Parkville, VIC,
Australia) for bisulfite conversion using the Zymo EZ
DNA Methylation kit (Zymo Research, Irvine, CA).
Bisulfite-treated DNA was hybridized to the 450K arrays
and the arrays were processed following standard proto-
cols. Samples were randomized across arrays according
to treatment group, sex and date of birth.
Normalization of the raw intensity data was performed
using the dasen method from the Bioconductor software
package wateRmelon [52]. The union of probes located
on the sex chromosomes (n = 11,648), probes targeting
CpGs located two or fewer nucleotides from a known
single nucleotide polymorphism (SNP) with a minor al-
lele frequency >0.05 (n = 29,476), and known cross-
hybridizing probes (n = 30,969) [53] were excluded from
the analysis. Probes were also excluded if they failed in
one or more samples, based on a detection P value >0.05.
Principal components analysis showed that batch
effects were present across the slides (groups of 12
arrays) for the arrays at birth, but not at age 5 years.
These batch effects for the arrays at birth were removed
using the Harman software package [54]. This method
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computes, and removes as noise, batch-to-batch variabil-
ity in the data to the extent that it cannot be accounted
for by the observed biological variance with an accept-
able probability. The batch noise was removed with the
trade-off coefficient set at 95% in favour of preserving
(biological) signal, i.e. the probability of losing genuine
signal in the process of removing noise was kept at 0.05.
Newborn data after batch correction was used in all ana-
lyses, except for the analysis of variably methylated
regions (VMRs) that showed SNP-associated effects.
The genome-wide DNA methylation data was first
used to give an estimate of the global DNA methylation
level at birth. The mean beta value for all probes on the
array was calculated as well as the mean beta for probes
based on their genomic annotation according to the Illu-
mina 450K manifest file. A Welch unequal variance t
test was used for comparison of global methylation
levels between the treatment groups and sexes.
To identify differentially methylated probes in the DHA
group compared to the control group, the limma package
[55] was used on quantile normalized beta values to com-
pute a moderated t test. Analyses were performed with ad-
justment for the stratification variables parity and centre of
birth, as well as sex. The analyses were also performed with
and without an adjustment for cell mixture using reference
data on cell-specific DNA methylation signatures for cord
blood [46]. Since adjustment for cell mixture did not
significantly change the main study outcomes (Additional
file 1: Table S3), only uncorrected data is presented in the
main paper. P values were corrected for multiple testing
using the Benjamini-Hochberg method [56] and significant
differentially methylated probes were identified based on a
false discovery rate (FDR) P value <0.05.
Testing for VMRs, independent of treatment group, and
for differently methylated regions (DMRs) between the
treatment groups was carried out using the Bioconductor
package DMRcate [57], which extracts these regions via
kernel density modelling. Since there were no limma-
significant probes in the treatment group comparison
(FDR-adjusted P < 0.05) to search for DMRs, we relaxed
the DMRcate default parameters that threshold signifi-
cance based on the number of limma-significant probes.
Parameterizations included a bandwidth size of 500 bp = 1
standard deviation of Gaussian kernel support, non-
default manual settings for the call to DMRcate of P
cut-off = 0.05 for VMRs and 0.001 for DMRs, and selec-
tion of regions consisting of at least two consecutive CpG
sites. To test the likelihood of detecting false-positive
DMRs, we compared the number of significant DMRs
called with an FDR P value cut-off of <0.001 for the treat-
ment group comparison to the number of DMRs that
would be identified by chance, using 500 random permu-
tations of the group variable for DMRcate.
The association of DNA methylation at birth with
cord blood DHA concentration, independently of
treatment group, was tested using linear regression,
again via limma, both with and without adjustment
for gestational age.
Adelaide mothers were randomized
N=1660
DHA: N=829, Control:N=831
Children attended 5 yr appointment
N=1408
DHA:N=714, Control:N=694
DNA available from 
Guthrie cards
N=991
DHA: N=517, Control: N=474
DNA available from blood 
leukocytes at age 5 yrs
N=667
DHA: N=342, Control: N=325
DNA available at birth and age 5 yrs
N=542
DHA:N=282, Control: N=260
Subset at age 5 yrs 
N=65








DHA: N=190, Control: N=179
Mothers consented to follow up study
N=1531
DHA:N=770,Control:N=761
Fig. 4 Flow diagram of the number of children included in the study
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and control group at birth with adjustment for cell mixture. Table S4. DMRs
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